Try our Advanced Search for more refined results

Teva Pharmaceuticals International GmbH et al v. Eli Lilly and Company

  1. September 26, 2023

    Eli Lilly Gets $177M Teva Migraine Drug Patent Verdict Tossed

    A Massachusetts federal judge overturned a $176.5 million migraine drug patent infringement verdict that Teva Pharmaceuticals won against Eli Lilly & Co., finding Tuesday that the three patents related to Teva's product Ajovy are invalid.

  2. May 22, 2023

    What IP Attys Should Know About Enablement After Amgen

    The same patent enablement standard that has existed for centuries must be applied to modern antibody patents, the U.S. Supreme Court ruled last week, prompting attorneys to review current patents and applications and look closely at enablement in litigation and prosecution.

  3. March 02, 2023

    Eli Lilly Says 'Vitriol' Behind Teva's Bid To Triple IP Verdict

    Eli Lilly & Co. has pushed back on rival Teva Pharmaceuticals' request to triple a $176.5 million migraine drug patent infringement verdict, saying Teva's motion resorted to "vitriol" by misconstruing the record and presenting facts selectively.

  4. February 10, 2023

    Teva Slams Lilly's 'Scorched-Earth' Tactics In Migraine Battle

    Teva Pharmaceuticals urged a Boston federal judge to triple the $176.5 million verdict it won after convincing a jury that Eli Lilly & Co. infringed three of its migraine drug patents and requested attorney fees be awarded due to its rival's "scorched-earth litigation strategy."

  5. November 09, 2022

    Teva Wins $176M From Eli Lilly In Migraine Drug Patent Trial

    A Boston federal jury on Wednesday ordered Eli Lilly & Co. to pay $176.5 million to Teva Pharmaceuticals after finding that its migraine drug Emgality willfully infringed three Teva patents.

  6. November 08, 2022

    Eli Lilly Flips Teva 'Free Ride' Claim As Migraine Trial Wraps

    Three weeks after Teva Pharmaceuticals opened a patent infringement suit by accusing Eli Lilly and Co. of free riding on intellectual property undergirding its migraine drug, Lilly told the jury Tuesday its rival is the real culprit after it "hopped into a de-risked market."

  7. October 19, 2022

    Teva Slams Eli Lilly's 'Free Ride' On Migraine IP As Trial Opens

    Teva Pharmaceuticals kicked off its migraine drug patent infringement trial against Eli Lilly and Co. on Wednesday, telling a Boston federal jury that the rival shouldn't be allowed to "free ride" on its hard-won research to rake in sales for a similar treatment.

  8. October 04, 2022

    Eli Lilly Can't Slip Teva's Migraine Drug Patent Suit

    Drugmakers Eli Lilly and Co. and Teva Pharmaceuticals must take their patent dispute over rival migraine medications to a jury, a Massachusetts federal judge said Monday, denying the bulk of the companies' dueling motions for summary judgment.

  9. August 11, 2022

    IP Forecast: Tesla Wants To Steer Secrets Case Out Of Court

    Tesla will tell a California federal judge next week that an employment agreement now warrants arbitration of its trade secrets case against an engineer who helped develop a supercomputer powering the company's self-driving cars. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  10. January 11, 2022

    No Sanctions For Eli Lilly In Teva Migraine Drug Patent Row

    Eli Lilly won't be sanctioned in a battle with Teva Pharmaceuticals over patents tied to a migraine biologic, a Massachusetts federal judge ruled in an order made public Tuesday, saying Eli Lilly didn't violate a court order requiring it to use specific search terms in electronically stored information.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!